Evidence map›Paper›PMID 39912924›Full record

ArticleApplied microbiology and biotechnology2025

Expansion of induced pluripotent stem cells under consideration of bioengineering aspects: part 2.

Misha Alexander Teale, Samuel Lukas Schneider, Stefan Seidel, Jürgen Krasenbrink, Martin Poggel, Dieter Eibl, Marcos F Q Sousa, Regine Eibl

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Applied microbiology and biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Misha Alexander TealeCentre for Cell Cultivation Techniques, Tissue Engineering, and Medical Biology, Institute of Chemistry and Biotechnology, ZHAW Zurich University of Applied Sciences, Grüentalstrasse 14, 8820, Wädenswil, Switzerland.ORCID http://orcid.org/0000-0003-0599-4115
Samuel Lukas SchneiderCentre for Cell Cultivation Techniques, Tissue Engineering, and Medical Biology, Institute of Chemistry and Biotechnology, ZHAW Zurich University of Applied Sciences, Grüentalstrasse 14, 8820, Wädenswil, Switzerland.ORCID http://orcid.org/0000-0002-2756-408X
Stefan SeidelCentre for Cell Cultivation Techniques, Tissue Engineering, and Medical Biology, Institute of Chemistry and Biotechnology, ZHAW Zurich University of Applied Sciences, Grüentalstrasse 14, 8820, Wädenswil, Switzerland.ORCID http://orcid.org/0000-0002-5244-0855
Jürgen KrasenbrinkAdvanced Manufacturing-Platform Engineering and Support, Bayer AG, Kaiser-Wilhelm-Allee 1, 51373, Leverkusen, Germany.
Martin PoggelAdvanced Manufacturing-Platform Engineering and Support, Bayer AG, Kaiser-Wilhelm-Allee 1, 51373, Leverkusen, Germany.
Dieter EiblCentre for Cell Cultivation Techniques, Tissue Engineering, and Medical Biology, Institute of Chemistry and Biotechnology, ZHAW Zurich University of Applied Sciences, Grüentalstrasse 14, 8820, Wädenswil, Switzerland.ORCID http://orcid.org/0000-0003-0033-3393
Marcos F Q SousaAdvanced Manufacturing-Platform Engineering and Support, Bayer AG, Kaiser-Wilhelm-Allee 1, 51373, Leverkusen, Germany. marcos.sousa1@bayer.com.ORCID http://orcid.org/0000-0003-3766-3900
Regine EiblCentre for Cell Cultivation Techniques, Tissue Engineering, and Medical Biology, Institute of Chemistry and Biotechnology, ZHAW Zurich University of Applied Sciences, Grüentalstrasse 14, 8820, Wädenswil, Switzerland.ORCID http://orcid.org/0000-0002-1840-8253

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The manufacturing of allogeneic cell therapeutics based on human-induced pluripotent stem cells (hiPSCs) holds considerable potential to revolutionize the accessibility and affordability of modern healthcare. However, achieving the cell yields necessary to ensure robust production hinges on identifying suitable and scalable single-use (SU) bioreactor systems. While specific stirred SU bioreactor types have demonstrated proficiency in supporting hiPSC expansion at L-scale, others, notably instrumented SU multiplate and fixed-bed bioreactors, remain relatively unexplored. By characterizing these bioreactors using both computational fluid dynamics and experimental bioengineering methods, operating ranges were identified for the Xpansion

Indexed as

BioengineeringBioreactorsCell Culture TechniquesInduced Pluripotent Stem CellsCell DifferentiationCell ProliferationCell SurvivalHumansAdherent cell cultureAllogeneicFixed-bed bioreactorMultiplate bioreactorPerfusionSingle-use bioreactor

Identifiers

PMID39912924
PMCPMC11802622

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.